Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting
Introduction: Severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) infection is characterised by a viral phase and a severe pro-inflammatory phase. The inhibition of the JAK/STAT pathway limits the pro-inflammatory state in moderate to severe COVID-19. Methodology: We analysed the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2022-01-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/15126 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850148172636094464 |
|---|---|
| author | Roberto Ovilla-Martinez Xochitl Cota-Rangel Jose De La Peña-Celaya Mariana Alejandra Alvarado-Zepeda Alejandro Jiménez Sastré Humberto Azuara Forcelledo Bernardino Ordoñez Rodriguez Juan Pulido Broca Aaron Molina Jaimes Alejandro Muñiz-Carvajal Maria Magdalena Bahena García Eduardo Cervera Ceballos Nidia Paulina Zapata Canto Jorge Oscar García Mendez Omar Noel García Jímenez Jesus Alberto Salas Heredia Javier Solis Soto Ruben Alberto Villalobos Mendez Gregorio Ignacio Ibarra Cindy Ledesma de la Cruz Nora Araujo Martinez Jessi Juárez Lara Cecilio Omar Ceballos Zuñiga Felipe Vicente Villaseñor Pérez Jose Carlos Herrera Garcia Patricia Nuche Salazar Alfredo Dominguez Paregrina Bertha Arizpe Bravo Gabriela Enciso Figueroa Teresita Trujillo Adriana Miguel Álvarez Diego de Jesús García Gallegos Alejandro Ortiz Arroyo Claudia Ivette Solorzano Soto Hiram Javier Jaramillo Ramírez Ibis De la Cruz Hernández Sergio De Gante Martínez Guadalupe Esmeralda Montesinos Gómez Silvia Martínez Velasco Roberto García Graullera Miguel Angel Vázquez López Victor Itaí Urbalejo Ceniceros Yolanda Lugo García Ana Itamar González Ávila Jorge Duque Rodriguez Rodolfo Ruiz Luján Violeta I. Rodríguez Rivera Lucio Soberanes Ramírez Pamela Elena Baez-Islas |
| author_facet | Roberto Ovilla-Martinez Xochitl Cota-Rangel Jose De La Peña-Celaya Mariana Alejandra Alvarado-Zepeda Alejandro Jiménez Sastré Humberto Azuara Forcelledo Bernardino Ordoñez Rodriguez Juan Pulido Broca Aaron Molina Jaimes Alejandro Muñiz-Carvajal Maria Magdalena Bahena García Eduardo Cervera Ceballos Nidia Paulina Zapata Canto Jorge Oscar García Mendez Omar Noel García Jímenez Jesus Alberto Salas Heredia Javier Solis Soto Ruben Alberto Villalobos Mendez Gregorio Ignacio Ibarra Cindy Ledesma de la Cruz Nora Araujo Martinez Jessi Juárez Lara Cecilio Omar Ceballos Zuñiga Felipe Vicente Villaseñor Pérez Jose Carlos Herrera Garcia Patricia Nuche Salazar Alfredo Dominguez Paregrina Bertha Arizpe Bravo Gabriela Enciso Figueroa Teresita Trujillo Adriana Miguel Álvarez Diego de Jesús García Gallegos Alejandro Ortiz Arroyo Claudia Ivette Solorzano Soto Hiram Javier Jaramillo Ramírez Ibis De la Cruz Hernández Sergio De Gante Martínez Guadalupe Esmeralda Montesinos Gómez Silvia Martínez Velasco Roberto García Graullera Miguel Angel Vázquez López Victor Itaí Urbalejo Ceniceros Yolanda Lugo García Ana Itamar González Ávila Jorge Duque Rodriguez Rodolfo Ruiz Luján Violeta I. Rodríguez Rivera Lucio Soberanes Ramírez Pamela Elena Baez-Islas |
| author_sort | Roberto Ovilla-Martinez |
| collection | DOAJ |
| description |
Introduction: Severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) infection is characterised by a viral phase and a severe pro-inflammatory phase. The inhibition of the JAK/STAT pathway limits the pro-inflammatory state in moderate to severe COVID-19.
Methodology: We analysed the data obtained by an observational cohort of patients with SARS-CoV-2 pneumonia treated with ruxolitinib in 22 hospitals of Mexico. The applied dose was determined based on physician’s criteria. The benefit of ruxolitinib was evaluated using the 8-points ordinal scale developed by the NIH in the ACTT1 trial. Duration of hospital stay, changes in pro-inflammatory laboratory values, mortality, and toxicity were also measured.
Results: A total of 287 patients were reported at 22 sites in Mexico from March to June 2020; 80.8% received ruxolitinib 5 mg BID and 19.16% received ruxolitinib 10 mg BID plus standard of care. At beginning of treatment, 223 patients were on oxygen support and 59 on invasive ventilation. The percentage of patients on invasive ventilation was 53% in the 10 mg and 13% in the 5 mg cohort. A statistically significant improvement measured as a reduction by 2 points on the 8-point ordinal scale was described (baseline 5.39 ± 0.93, final 3.67± 2.98, p = 0.0001). There were 74 deaths. Serious adverse events were presented in 6.9% of the patients.
Conclusions: Ruxolitinib appears to be safe in COVID-19 patients, with clinical benefits observed in terms of decrease in the 8-point ordinal scale and pro-inflammatory state. Further studies must be done to ensure efficacy against mortality.
|
| format | Article |
| id | doaj-art-88c4992fd7b64d6ba37e3ea46a9ed0d9 |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-88c4992fd7b64d6ba37e3ea46a9ed0d92025-08-20T02:27:19ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802022-01-01160110.3855/jidc.15126Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world settingRoberto Ovilla-Martinez0Xochitl Cota-Rangel1Jose De La Peña-Celaya2Mariana Alejandra Alvarado-Zepeda3Alejandro Jiménez Sastré4Humberto Azuara Forcelledo5Bernardino Ordoñez Rodriguez6Juan Pulido Broca7Aaron Molina Jaimes8Alejandro Muñiz-Carvajal9Maria Magdalena Bahena García10Eduardo Cervera Ceballos11Nidia Paulina Zapata Canto12Jorge Oscar García Mendez13Omar Noel García Jímenez14Jesus Alberto Salas Heredia15Javier Solis Soto16Ruben Alberto Villalobos Mendez17Gregorio Ignacio Ibarra18Cindy Ledesma de la Cruz19Nora Araujo Martinez20Jessi Juárez Lara21Cecilio Omar Ceballos Zuñiga22Felipe Vicente Villaseñor Pérez23Jose Carlos Herrera Garcia24Patricia Nuche Salazar25Alfredo Dominguez Paregrina26Bertha Arizpe Bravo27Gabriela Enciso Figueroa28Teresita Trujillo29Adriana Miguel Álvarez30Diego de Jesús García Gallegos31Alejandro Ortiz Arroyo32Claudia Ivette Solorzano Soto33Hiram Javier Jaramillo Ramírez34Ibis De la Cruz Hernández35Sergio De Gante Martínez36Guadalupe Esmeralda Montesinos Gómez37Silvia Martínez Velasco38Roberto García Graullera39Miguel Angel Vázquez López40Victor Itaí Urbalejo Ceniceros41Yolanda Lugo García42Ana Itamar González Ávila43Jorge Duque Rodriguez44Rodolfo Ruiz Luján45Violeta I. Rodríguez Rivera46Lucio Soberanes Ramírez47Pamela Elena Baez-Islas48Hematology, Hospital Angeles Lomas, Huixquilucan, MexicoHematology, Hospital Angeles Lomas, Huixquilucan, MexicoHematology, Hospital Angeles Lomas, Huixquilucan, MexicoInternal Medicine, Centro Medico de Especialidades Ciudad Juarez, Ciudad Juarez, Chihuahua, MexicoInternal Medicine, Instituto de Seguridad Social del Estado de Tabasco, Villahermosa, Tabasco, MexicoInternal Medicine, Instituto de Seguridad Social del Estado de Tabasco, Villahermosa, Tabasco, MexicoInternal Medicine, Instituto de Seguridad Social del Estado de Tabasco, Villahermosa, Tabasco, MexicoInternal Medicine, Instituto de Seguridad Social del Estado de Tabasco, Villahermosa, Tabasco, MexicoInfectology, ISSSTE Hospital Regional Tipo B de Alta Especialidad Bicentenario de la Independencia, Tultitlan de Mariano Escobedo, MexicoInternal Medicine, Hospital General De Cancún "Jesús Kumate Rodriguez", Cancun, Quintana Roo, MexicoHematology, Hospital Central Sur de Alta Especialidad PEMEX, Mexico City, MexicoHematology, Medica Sur, Mexico City, MexicoHematology, Medica Sur, Mexico City, MexicoHematology, Medica Sur, Mexico City, MexicoInternal Medicine, Hospital General Regional No 66 IMSS, Ciudad Juarez, Chihuahua, MexicoIntensive Care, Hospital Star Medica Ciudad Juarez, Ciudad Juarez, Chihuahua, MexicoIntensive Care, Hospital Star Medica Ciudad Juarez, Ciudad Juarez, Chihuahua, MexicoIntensive Care, Hospital Regional de PEMEX Salamanca, Salamanca, Guanajuato, MexicoHematology, Hospital General Regional 1 Dr. Carlos Mac Gregor Sanchez Navarro IMSS, Mexico City, MexicoHematology, Hospital General Regional 1 Dr. Carlos Mac Gregor Sanchez Navarro IMSS, Mexico City, MexicoInternal Medicine, Centro Medico de Especialidades Ciudad Juarez, Ciudad Juarez, Chihuahua, MexicoHematology, Hospital General Regional 1 Dr. Carlos Mac Gregor Sanchez Navarro IMSS, Mexico City, MexicoPneumology, Hospital de la Familia, Mexicali, Baja California, MexicoHematology, Hospital General Regional 1 Dr. Carlos Mac Gregor Sanchez Navarro IMSS, Mexico City, MexicoPneumology, Grupo Medico en Contra del Coronavirus, Puebla, Puebla, MexicoPneumology, Grupo Medico en Contra del Coronavirus, Puebla, Puebla, MexicoPneumology, Grupo Medico en Contra del Coronavirus, Puebla, Puebla, MexicoPneumology, Grupo Medico en Contra del Coronavirus, Puebla, Puebla, MexicoPneumology, Grupo Medico en Contra del Coronavirus, Puebla, Puebla, MexicoPneumology, Grupo Medico en Contra del Coronavirus, Puebla, Puebla, MexicoHematology, Hospital General Regional 1 Dr. Carlos Mac Gregor Sanchez Navarro IMSS, Mexico City, MexicoIntensive Care, Hospital General de Zona 10 IMSS, Manzanillo, Colima, MexicoInternal Medicine, Centro Medico de Especialidades Ciudad Juarez, Ciudad Juarez, Chihuahua, MexicoIntensive Care, Hospital General de Zona 18 IMSS, Playa del Carmen, Quintana Roo, MexicoInternal Medicine, Hospital General de Mexicali, Mexicali, Baja California, MexicoInternal Medicine, Hospital General de Zona 46 IMSS, Villahermosa, Tabasco, MexicoInternal Medicine, Hospital Angeles Ciudad Juárez, Ciudad Juarez, Chihuahua, MexicoInternal Medicine, Hospital General de Zona 46 IMSS, Villahermosa, Tabasco, MexicoInternal Medicine, Hospital General de Zona 46 IMSS, Villahermosa, Tabasco, MexicoInternal Medicine, Hospital General de Zona 3 IMSS, Cancun, Quintana Roo, MexicoInternal Medicine, Hospital General de Zona 2 IMSS, Tuxtla Gutierrez, Chiapas, MexicoHematology, Instituto Nacional de Cancerología, Mexico City, MexicoHematology, Hospital General Regional 1 Dr. Carlos Mac Gregor Sanchez Navarro IMSS, Mexico City, MexicoHematology, Hospital General Regional 1 Dr. Carlos Mac Gregor Sanchez Navarro IMSS, Mexico City, MexicoHematology, Hospital Ángeles Chihuahua, Chihuahua, Chihuahua, MexicoInternal Medicine, Hospital General de Mexicali, Mexicali, Baja California, MexicoGastroenterology, Gastroclinic, Torreon, Coahuila, MexicoIntensive Care, Hospital General Agustín O' Horan, Merida, Quintana Roo, MexicoHematology, Hospital Angeles Lomas, Huixquilucan, Mexico Introduction: Severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) infection is characterised by a viral phase and a severe pro-inflammatory phase. The inhibition of the JAK/STAT pathway limits the pro-inflammatory state in moderate to severe COVID-19. Methodology: We analysed the data obtained by an observational cohort of patients with SARS-CoV-2 pneumonia treated with ruxolitinib in 22 hospitals of Mexico. The applied dose was determined based on physician’s criteria. The benefit of ruxolitinib was evaluated using the 8-points ordinal scale developed by the NIH in the ACTT1 trial. Duration of hospital stay, changes in pro-inflammatory laboratory values, mortality, and toxicity were also measured. Results: A total of 287 patients were reported at 22 sites in Mexico from March to June 2020; 80.8% received ruxolitinib 5 mg BID and 19.16% received ruxolitinib 10 mg BID plus standard of care. At beginning of treatment, 223 patients were on oxygen support and 59 on invasive ventilation. The percentage of patients on invasive ventilation was 53% in the 10 mg and 13% in the 5 mg cohort. A statistically significant improvement measured as a reduction by 2 points on the 8-point ordinal scale was described (baseline 5.39 ± 0.93, final 3.67± 2.98, p = 0.0001). There were 74 deaths. Serious adverse events were presented in 6.9% of the patients. Conclusions: Ruxolitinib appears to be safe in COVID-19 patients, with clinical benefits observed in terms of decrease in the 8-point ordinal scale and pro-inflammatory state. Further studies must be done to ensure efficacy against mortality. https://jidc.org/index.php/journal/article/view/15126COVID-19pneumoniaruxolitinibJAK/STAT inhibitors |
| spellingShingle | Roberto Ovilla-Martinez Xochitl Cota-Rangel Jose De La Peña-Celaya Mariana Alejandra Alvarado-Zepeda Alejandro Jiménez Sastré Humberto Azuara Forcelledo Bernardino Ordoñez Rodriguez Juan Pulido Broca Aaron Molina Jaimes Alejandro Muñiz-Carvajal Maria Magdalena Bahena García Eduardo Cervera Ceballos Nidia Paulina Zapata Canto Jorge Oscar García Mendez Omar Noel García Jímenez Jesus Alberto Salas Heredia Javier Solis Soto Ruben Alberto Villalobos Mendez Gregorio Ignacio Ibarra Cindy Ledesma de la Cruz Nora Araujo Martinez Jessi Juárez Lara Cecilio Omar Ceballos Zuñiga Felipe Vicente Villaseñor Pérez Jose Carlos Herrera Garcia Patricia Nuche Salazar Alfredo Dominguez Paregrina Bertha Arizpe Bravo Gabriela Enciso Figueroa Teresita Trujillo Adriana Miguel Álvarez Diego de Jesús García Gallegos Alejandro Ortiz Arroyo Claudia Ivette Solorzano Soto Hiram Javier Jaramillo Ramírez Ibis De la Cruz Hernández Sergio De Gante Martínez Guadalupe Esmeralda Montesinos Gómez Silvia Martínez Velasco Roberto García Graullera Miguel Angel Vázquez López Victor Itaí Urbalejo Ceniceros Yolanda Lugo García Ana Itamar González Ávila Jorge Duque Rodriguez Rodolfo Ruiz Luján Violeta I. Rodríguez Rivera Lucio Soberanes Ramírez Pamela Elena Baez-Islas Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting Journal of Infection in Developing Countries COVID-19 pneumonia ruxolitinib JAK/STAT inhibitors |
| title | Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting |
| title_full | Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting |
| title_fullStr | Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting |
| title_full_unstemmed | Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting |
| title_short | Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting |
| title_sort | ruxolitinib as a treatment strategy for sars cov 2 pneumonia clinical experience in a real world setting |
| topic | COVID-19 pneumonia ruxolitinib JAK/STAT inhibitors |
| url | https://jidc.org/index.php/journal/article/view/15126 |
| work_keys_str_mv | AT robertoovillamartinez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT xochitlcotarangel ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT josedelapenacelaya ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT marianaalejandraalvaradozepeda ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT alejandrojimenezsastre ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT humbertoazuaraforcelledo ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT bernardinoordonezrodriguez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT juanpulidobroca ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT aaronmolinajaimes ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT alejandromunizcarvajal ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT mariamagdalenabahenagarcia ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT eduardocerveraceballos ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT nidiapaulinazapatacanto ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT jorgeoscargarciamendez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT omarnoelgarciajimenez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT jesusalbertosalasheredia ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT javiersolissoto ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT rubenalbertovillalobosmendez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT gregorioignacioibarra ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT cindyledesmadelacruz ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT noraaraujomartinez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT jessijuarezlara ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT cecilioomarceballoszuniga ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT felipevicentevillasenorperez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT josecarlosherreragarcia ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT patricianuchesalazar ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT alfredodominguezparegrina ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT berthaarizpebravo ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT gabrielaencisofigueroa ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT teresitatrujillo ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT adrianamiguelalvarez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT diegodejesusgarciagallegos ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT alejandroortizarroyo ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT claudiaivettesolorzanosoto ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT hiramjavierjaramilloramirez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT ibisdelacruzhernandez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT sergiodegantemartinez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT guadalupeesmeraldamontesinosgomez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT silviamartinezvelasco ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT robertogarciagraullera ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT miguelangelvazquezlopez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT victoritaiurbalejoceniceros ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT yolandalugogarcia ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT anaitamargonzalezavila ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT jorgeduquerodriguez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT rodolforuizlujan ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT violetairodriguezrivera ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT luciosoberanesramirez ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting AT pamelaelenabaezislas ruxolitinibasatreatmentstrategyforsarscov2pneumoniaclinicalexperienceinarealworldsetting |